the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
August 23, 2019 – Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal viral disease characterized by progressive damage or inflammation of the white matter of the brain at multiple locations (i.e., multifocal). It is caused by the JC virus, after …
Therapies that promote progressive multifocal leukoencephalopathy (PML) Read more »
August 06, 1015 – The American Food and Drug Administration (FDA) has just issued a warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Fingolimod (Gilenya) for …
June 6, 2011 – Today, we learn from Health Canada the following very important safety information: Hoffmann-La Roche Limited, in consultation with Health Canada, would like to inform you of important new safety information regarding fatal infusion related reactions following …
October 23, 2009 – Today, Genentech and FDA notified healthcare professionals about a third case of progressive multifocal leukoencephalopathy [PML], the first case of PML in a patient with rheumatoid arthritis [RA] treated with Rituximab [Rituxan] who has not previously …
Rituximab [Rituxan] – Progressive Multifocal Leukoencephalopathy [PML] Read more »